Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

Cancer

Research Field Genetics

Kallikrein Dream

| Roisin McGuigan

Eleftherios P. Diamandis, Hold ’em for Life Chair in Prostate Cancer Biomarkers, University of Toronto.

Research Field Cancer

Leidenfrost Nanochemistry

| James Strachan

Scientists fabricate anticancer nanoparticles by recreating deep sea volcano chemistry.

Tools & Techniques Cancer

Rush at Your Peril

| Eleftherios P. Diamandis

False discoveries have plagued biomarker research for years: don't trust everything you read.

Tools & Techniques Cancer

CEA: Overlooked and Underused

| Roisin McGuigan

Could an existing blood test improve treatment choices – and outcomes – for some colon cancer patients?

Tools & Techniques Cancer

Getting Smart with Clinical Trials

| Joy Yucaitis

Liquid biopsy technology could help boost clinical trial success.

Research Field Omics

Embracing the Proteogenomic Toolkit

| Andreas Hühmer

To win the war on cancer, we need to put proteomics on an equal footing with genomics.

Tools & Techniques Cancer

The Rise of ctDNA, Part Two

| Michael Schubert

Circulating tumor DNA profiling can yield new insights into early-stage lung cancer evolution.

Tools & Techniques Cancer

The Rise of ctDNA, Part One

| Roisin McGuigan

New ctDNA assays could make more metastatic melanoma cases detectable.

Tools & Techniques Cancer

Cracking Cancer’s Code

| Roisin McGuigan

Sitting Down With George Calin, Professor, The University of Texas MD Anderson Cancer Center, USA.

Tools & Techniques Cancer

A Winning Combination?

| Roisin McGuigan

Engineering more effective antibody-drug conjugates.

Newsletter

Send me the latest from The Translational Scientist.

Sign up now

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register